FdaApplication
BLA 761063
Identifiers
- fda_app_no: BLA761063
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 2018-09-27 |
Revenue by product
EMGALITY
| Period | Revenue |
|---|---|
| Q4 2024 | $249.8M |
| Q3 2024 | $202.9M |
| Q2 2024 | $192.0M |
| Q1 2024 | $225.7M |
| Q4 2023 | $186.0M |
| Q3 2023 | $168.5M |
| Q2 2023 | $169.3M |
| Q1 2023 | $154.3M |
| Q4 2022 | $175.7M |
| Q3 2022 | $168.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
EMGALITY
| Period | Revenue |
|---|---|
| Q4 2024 | $249.8M |
| Q3 2024 | $202.9M |
| Q2 2024 | $192.0M |
| Q1 2024 | $225.7M |
| Q4 2023 | $186.0M |
| Q3 2023 | $168.5M |
| Q2 2023 | $169.3M |
| Q1 2023 | $154.3M |
| Q4 2022 | $175.7M |
| Q3 2022 | $168.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EMGALITY | GALCANEZUMAB-GNLM | 120MG/ML | Injection |
| EMGALITY | — | 100MG/ML | Injection |
| EMGALITY | — | 120MG/ML | Injection |
3 products